Updated 02:01 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,876.40 -0.25% CL 88.33 -0.26% BTC 64,613.34 +0.76%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,876 −0.25% BTC $64,613 +0.76% VIX 19.30 +3.21% latest tape · as of 02:01 UTC
The Screen · Healthcare · Medical Devices

Beta Bionics Inc

BBNX · NASDAQ · USD · Market cap $770M · 420 employees

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

FAIL · Does not pass the screen
16.42 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price16.42 USD at the 13 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 13 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.42)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $13.00 to $32.00, base estimate $20.00 (screen dated 2026-11-13).

Current read
Markup ?
Undervalued · screened 2026-11-13
  • Trend Markup
  • Insiders insiders sold, $6,508, latest filing 2026-11-05
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.42, read 2026-11-14
  • Ethical does not pass the values gate
Price16.42 USD
Fair value20.00
Ethical score70.0/100
Value readUndervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-03Read Distribution16.75-2.0% to today ✓Markdown gives way to Distribution with volume flow in agreement
2026-10-20Read Markdown17.31-5.1% to today ✓Markup gives way to Markdown with volume flow in agreement
2026-08-22Read Markup17.29-5.0% to today Accumulation gives way to Markup after a 19% rise in 7 weeks
2026-07-02Read Accumulation14.53+13.0% to today ✓First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Beta Bionics Inc holds its Markup at $16.42. The statistical read favours the buyers, held for 13 days.

As held on the ledger · 2026-11-13
PhaseMarkup
Quantitative stateThe statistical read favours the buyers, held for 13 days
Price at the screen$16.42
ValuationN/A trailing · -7.23 forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens, Shown in Full

Does not pass. Revenue purity

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 2.22% Below 33% Interest-bearing debt is just 2.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 13.82% Below 33% Cash held in interest-bearing accounts and securities is 13.8% of assets, under the one-third limit. Pass
Receivables 14.81% Below 49% Money owed to the company is 14.8% of assets, under the 49% limit. Pass
Revenue purity 10.90% Below 5% 10.9% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Beta Bionics clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 11% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when BBNX's ethical verdict changes

Today BBNX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly an 18% discount to our $20.00 fair value, none competitive moat, 56.60% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

13.00Conservative20.00Base case32.00Growth case 16.42Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 17.9% discount to the base estimate.

The Street's Range
13.00Street low 20.00Street average 32.00Street high 16.42Price

Third-party analyst targets: 10 covering, consensus Buy. The average target sits +22% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $20.00, with a range of $13.00 to $32.00, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it stands out

A 57%-growth business trading at just -7.2x forward earnings, with a none competitive moat. That is an 18% discount to our $20.00 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 10 analysts rate it Buy with a $20.00 average target, about 22% above the screened price.

The fundamentals · plain-English read
Forward P/E-7.2x
EPS, trailing-1.37
EPS, forward-2.39
Revenue growth+56.6%growing very fast
Profit margin-60.3%currently unprofitable
Return on equity-22.7%not currently earning a positive return on equity
FCF yield-5.72%
Debt to equity2.55heavy leverage: higher risk if revenue softens
Current ratio10.69comfortably covers its short-term bills
Short interest, float0.15%
52-week range8.80 - 32.71
MoatNONE
Market cap$770M
Employees420

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

BBNX trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-10 Distribution $16.95 +1.2% Entry 17

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.

2026-11-03 Distribution · changed $16.75 -3.2% Entry 16

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter.

2026-10-27 Markdown $17.31 +0.0% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Markdown $17.31 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Markdown $17.31 +0.0% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-24 Markdown $17.31 +0.0% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-23 Markdown $17.31 +0.0% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-22 Markdown $17.31 +0.0% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-21 Markdown $17.31 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-20 Markdown · changed $17.31 -1.8% Entry 8

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in BBNX's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · BBNX
DateInsiderTitleTypeSharesValue
2026-11-05 Feider Stephen CFO S - Sale+OE 382 $6,508
2026-10-27 Mensinger Mike Chief Product Officer S - Sale 2,650 $58,300
2026-10-26 Hopman Mark Chief Commercial Officer S - Sale 821 $16,420
2026-10-14 Hopman Mark Chief Commercial Officer S - Sale 775 $13,446
2026-09-09 Hopman Mark Chief Commercial Officer S - Sale 35,994 $664,550

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $9.85 +42.3% · $1,423 +42.3%
2 months $8.86 +58.2% · $1,582 +58.2%
3 months $10.11 +38.6% · $1,386 +38.6%
6 months $29.31 -52.2% · $478 -52.2%
1 year $19.27 -27.3% · $727 -27.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever BBNX does next, these words stay.

Beta Bionics Inc · BBNX · Markup · $16.42
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.